Chicago, IL – ASCO 2011 Annual Meeting: Nancy Daly, Martin Murphy, Kathleen Cooney Arti Hurria, Nancy Davidson, Raphael Catane, and Nora Anita Janjan spoke during the Conquer Cancer Grant and Awards Ceremony and Brunch at the American Society for Clinical Oncology Annual Meeting. Over 25,000 physicians, researchers and healthcare professionals from over 100 countries attended the meeting, which was held at the McCormick Convention center and featured the latest cancer research in the areas of basic and clinical science. Date: Sunday June 5, 2011 Photo by © GMG/Brian Powers 2011.
Dr. James Xu received his Bachelor of Science degree in chemical engineering with a minor in mathematics from Brigham Young University and his M.D. degree from University of Minnesota. He completed his internal medicine residency at the Yale-New Haven Hospital of Yale University in New Haven, CT, and his hematology and medical oncology fellowship at the New York-Presbyterian Hospital of Columbia University in New York City. Because of his unique background in engineering and medicine, Dr. Xu was the recipient of the prestigious ASCO (American Society of Clinical Oncology)-Conquer Cancer Foundation Young Investigator Award in 2011 and Merit Award in 2012. Dr. Xu is a strong advocate of precision medicine and he is the first person to have proposed and preliminarily confirmed the feasibility of using deep sequencing technology to detect genetic mutation in rare cell samples such as circulating tumor cells from cancer patients’ peripheral blood. He has published in peer-reviewed journals in lung, breast, and pancreatic cancers. Dr. Xu is board certified in internal medicine, hematology, and medical oncology.
Dr. Xu was an invited speaker at numerous most-respected national cancer institute-designated comprehensive cancer centers including M.D Anderson Cancer Center, Columbia University Medical Center, Roswell Park Cancer Institute etc. More recently, Dr. Xu has been invited to speak at several premier national and international scientific meetings including American Association for Cancer Research annual meeting, Chinese Society of Clinical Oncology-Society of Translational Oncology Joint Symposium, etc.
From 2013 to 2021, Dr. Xu was a medical officer at US Food and Drug Administration’s Office of Hematology and Oncology Products, during which he was the first person to propose the predictive biomarker for immunotherapy in advanced renal cell carcinoma.
Further, to contribute to our community, Dr. Xu has been active with MMCTV’s TV show, Housecall, advocating for cancer awareness, diagnosis and treatment.